558-P: Online Medical Education Advances Physicians’ Knowledge and Competence for the Use of Basal Insulin

Abstract

Background and aims: Despite various alternative treatment options basal insulin continues to play an important role in the management of patients with type 2 diabetes (T2D). The goal of this activity for primary care physicians (PCP) and diabetologists/endocrinologists (D/E) was to improve their understanding of the continued role of basal insulin in the management of T2D, address barriers to its initiation, and increase the awareness of novel once-weekly basal insulin formulations. Materials and methods: Two diabetes experts joined a 24-min online video discussion with synchronized slides. Educational effect was assessed using a repeated-pair design with pre-/post-assessment. 3 multiple choice questions assessed knowledge/competence, 1 question rated on a Likert-type scale assessed confidence. A paired samples t-test was conducted on overall average number of correct responses and for confidence rating, a McNemar’s test was conducted at the question level (5% significance level). Cohen’s d with correction for paired samples estimated the effect size of the education on number of correct responses. Data collection from 10/25/22 to 12/13/22. Results: • PCPs (n=73) improved their knowledge regarding basal insulin therapy in the management of T2D by 69% (p<.001) • D/E (n=126) improved their knowledge regarding the clinical profile of emerging once-weekly basal insulin formulations by 52% (p<.01) and their competence related to the identification of patients with T2D as suitable candidates for future treatment with once-weekly basal insulins by 192% (p<.001) • 40% of PCP (P<.001) and 31% of D/E (P<.001) increased their confidence in initiating basal insulin therapy in their patients with T2D Conclusion: Participation of D/E and PCP in an online video expert discussion improved their understanding of basal insulin therapy, the profile of emerging once-weekly formulations and the identification of appropriate patients with T2D significantly. Disclosure J.Trier: None. H.S.Bajaj: Research Support; Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Anji Pharmaceuticals, Eli Lilly and Company, Kowa Company, Ltd., Novo Nordisk, Pfizer Inc., Sanofi, Tricida, Inc. A.Philis-tsimikas: Advisory Panel; Dexcom, Inc., Novo Nordisk A/S, Sanofi, Other Relationship; Medtronic, Research Support; Novo Nordisk A/S, Lilly, Viking Therapeutics, NIH - National Institutes of Health.